Preemptive Pharmacogenetic-Guided Metoprolol Management for Postoperative Atrial Fibrillation in Cardiac Surgery: The Preemptive Pharmacogenetic-Guided Metoprolol Management for Atrial Fibrillation in Cardiac Surgery Pilot Trial

被引:1
作者
Staben, Rae [1 ]
Vnencak-Jones, Cindy L. [2 ]
Shi, Yaping [3 ]
Shotwell, Matthew S. [1 ,3 ]
Absi, Tarek [4 ]
Shah, Ashish S. [4 ]
Wanderer, Jonathan P. [1 ,5 ]
Beller, Marc [6 ]
Kertai, Miklos D. [1 ,7 ]
机构
[1] Vanderbilt Univ, Med Ctr, Dept Anesthesiol, Nashville, TN USA
[2] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA
[3] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA
[4] Vanderbilt Univ, Med Ctr, Dept Cardiac Surg, Nashville, TN USA
[5] Vanderbilt Univ, Med Ctr, Dept Biomed Informat, Nashville, TN USA
[6] Vanderbilt Univ, Med Ctr, Ctr Precis Med, Nashville, TN USA
[7] Vanderbilt Univ, Med Ctr, Dept Anesthesiol, 1211 21st Ave South,MAB 526, Nashville, TN 37212 USA
关键词
atrial fibrillation; cardiac surgery; beta-blockers; pharmacogenetic testing; CYP2D6; GENOTYPE; METABOLIZERS; ASSOCIATION; PHENOTYPE; RISK;
D O I
10.1053/j.jvca.2023.06.017
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Objectives: To test the hypothesis that implementation of a cytochrome P-450 2D6 (CYP2D6) genotype guided perioperative metoprolol administration will reduce the risk of postoperative atrial fibrillation (AF), the authors conducted the Preemptive Pharmacogenetic-Guided Metoprolol Management for Atrial Fibrillation in Cardiac Surgery pilot study. Design: Clinical pilot trial. Setting: Single academic center. Participants: Seventy-three cardiac surgery patients. Measurements and Main Results: Patients were classified as normal, intermediate, poor, or ultrarapid metabolizers after testing for their CYP2D6 genotype. A clinical decision support tool in the electronic health record advised providers on CYP2D6 genotype guided metoprolol dosing. Using historical data, the Bayesian method was used to compare the incidence of postoperative AF in patients with altered metabolizer status to the reference incidence. A logistic regression analysis was performed to study the association between the metabolizer status and postoperative AF while controlling for the Multicenter Study of Perioperative Ischemia AF Risk Index. Of the 73 patients, 30% (n = 22) developed postoperative AF; 89% (n = 65) were normal metabolizers; 11% (n = 8) were poor/intermediate metabolizers; and there were no ultrarapid metabolizer patients identified. The estimated rate of postoperative AF in patients with altered metabolizer status was 30% (95% CI 8%-60%), compared with the historical reference incidence (27%). In the risk-adjusted analysis, there was insufficient evidence to conclude that modifying metoprolol dosing based on poor/intermediate metabolizer status was associated significantly with the odds of postoperative AF (odds ratio 0.82, 95% CI 0.15-4.55, p = 0.82). Conclusions: A CYP2D6 genotype guided metoprolol management was not associated with a reduction of postoperative AF after cardiac surgery. (c) 2023 Published by Elsevier Inc.
引用
收藏
页码:1974 / 1982
页数:9
相关论文
共 36 条
  • [1] [Anonymous], 2001, J Postgrad Med, V47, P199
  • [2] Variations in Pharmacology of β-Blockers May Contribute to Heterogeneous Results in Trials of Perioperative β-Blockade
    Badgett, Robert G.
    Lawrence, Valerie A.
    Cohn, Steven L.
    [J]. ANESTHESIOLOGY, 2010, 113 (03) : 585 - 592
  • [3] Genetic Variation in the CYP2D6 Gene Is Associated With a Lower Heart Rate and Blood Pressure in β-Blocker Users
    Bijl, M. J.
    Visser, L. E.
    van Schaik, R. H. N.
    Kors, J. A.
    Witteman, J. C. M.
    Hofman, A.
    Vulto, A. G.
    van Gelder, T.
    Stricker, B. H. Ch
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (01) : 45 - 50
  • [4] A Meta-Analysis of CYP2D6 Metabolizer Phenotype and Metoprolol Pharmacokinetics
    Blake, C. M.
    Kharasch, E. D.
    Schwab, M.
    Nagele, P.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (03) : 394 - 399
  • [5] Cheruku Kiran K, 2004, Prev Cardiol, V7, P13, DOI 10.1111/j.1520-037X.2004.3117.x
  • [6] Consortium CPI, Clinical Pharmacogenetics Implementation Consortium
  • [7] HAZARDS OF POSTOPERATIVE ATRIAL ARRHYTHMIAS
    CRESWELL, LL
    SCHUESSLER, RB
    ROSENBLOOM, M
    COX, JL
    [J]. ANNALS OF THORACIC SURGERY, 1993, 56 (03) : 539 - 549
  • [8] Deroubaix X, 1996, INT J CLIN PHARM TH, V34, P61
  • [9] Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: The TREND statement
    Des Jarlais, DC
    Lyles, C
    Crepaz, N
    [J]. AMERICAN JOURNAL OF PUBLIC HEALTH, 2004, 94 (03) : 361 - 366
  • [10] Postoperative atrial fibrillation: mechanisms, manifestations and management
    Dobrev, Dobromir
    Aguilar, Martin
    Heijman, Jordi
    Guichard, Jean-Baptiste
    Nattel, Stanley
    [J]. NATURE REVIEWS CARDIOLOGY, 2019, 16 (07) : 417 - 436